Targeted busulfan/cyclophosphamide (TBU/CY) for allogeneic hematopoietic cell transplantation (HCT) carries a

Targeted busulfan/cyclophosphamide (TBU/CY) for allogeneic hematopoietic cell transplantation (HCT) carries a high risk of sinusoidal obstruction syndrome (SOS) in patients transplanted for myelofibrosis. followed by daily IV BU for four days targeted to a concentration at steady state (Css) of 800-900 ng/mL. CY/TBU-conditioned patients had higher exposure to CY (p